THE USE OF PCSK9-TARGETED THERAPY IN PATIENTS WITH CORONARY HEART DISEASE AND AORTIC VALVE STENOSIS AFTER SURGERY (CLINICAL EXAMPLES OF AN EXPLORATORY RESEARCH STUDY)

Highlights

• The relevance of the clinical case is related to the high incidence of Fallot's tetrad and the need for complex cardiac surgery, including prosthetics of the excretory right ventricle.
• The development and application of high-quality conduits, such as Pylon, is important for improving surgical outcomes in children.

Abstract

In this paper, using clinical examples of two patients from an exploratory scientific study with an established diagnosis of coronary heart disease and operated aortic valve stenosis, an analysis of the efficacy and safety of using a PCSK9 inhibitor (alirocumab) as part of a combination lipid-lowering therapy prescribed for the correction of dyslipidemia over 4 months of treatment is presented. It is shown that over 4 months of the exploratory scientific study, despite the high safety of the prescribed treatment, the reduction in low-density lipoprotein cholesterol in this category of patients remains suboptimal and is not accompanied by the achievement of its target values, which justifies the need for additional optimization of lipidological treatment as part of cardiovascular risk management.

1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020; 41 (1): 111–88. doi: 10.1093/eurheartj/ehz4558.

2. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. The Lancet. 2010; 376 (9753): 1670–81. doi: 10.1016/S0140-6736(10)61350-5.

3. Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38 (32): 2459–2472. doi: 10.1093/eurheartj/ehx144.

4. Arutyunov G.P., Ezhov M.V., Alieva A.S., Shaposhnik I.I., Orlova Y.A., Koziolova N.A., Tarlovskaya E.I., Grigorieva N. Y., Chesnikova A.I. Hypolipidemic therapy in special situations. The Journal of Atherosclerosis and Dyslipidemias. 2024; 3 (56): 84–99. doi: 10.34687/2219-8202.JAD.2024.03.0008. (In Russ).

5. Ray K.K., Reeskamp L.F., Laufs U. et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022; 43 (8): 830–833. doi: 10.1093/eurheartj/ehab718.

6. Oganov R.G., Kukharchuk V.V., Arutyunov G.P., Galyavich A.S., Gurevich V.S., et al. Persistent abnormalities of lipid spectrum parameters in patients with dyslipidemia receiving statins in real clinical practice in the Russian Federation (Russian part of the DYSIS study). Cardiovascular Therapy and Prevention. 2012; 11 (4): 70–78. doi: 10.15829/1728-8800-2012-4-70-78. (In Russ).

7. Ray K.K., Molemans B., Schoonen W.M., Giovas P., Bray S., et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021; 28 (11): 1279–1289. doi: 10.1093/eurjpc/zwaa047.

8. Ray K.K., Aguiar C., Arca M., Connolly D.L., Eriksson M., et al. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024; 31 (15): 1792–1803. doi: 10.1093/eurjpc/zwae199.

9. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023; 28 (5): 5471. doi: 10.15829/1560-4071-2023-5471. (In Russ)

10. Sapina A.I., Varlamova Yu.Yu., Papyrina M.G., Bezymyanny A.S., Kordzaya E.L., et al. Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare. Russian Journal of Cardiology. 2024; 29 (6): 5943. doi: 10.15829/1560-4071-2024-5943. (In Russ)

11. Tokgözoğlu L., Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022; 43 (34): 3198–3208. doi: 10.1093/eurheartj/ehab841.

12. Voevoda M.I., Gurevich V.S., Ezhov M.V., Sergienko I.V. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022; 62 (6): 57–62. doi: 10.18087/cardio.2022.6.n2115. (In Russ)

13. Chubykina U.V., Tyurina A.V., Ezhov M.V. The era of targeted therapy for hyperlipidemia. Russian Journal of Cardiology. 2024; 29 (8): 6038. doi: 10.15829/1560-4071-2024-6038. (In Russ)

14. Pawade T.A., Newby D.E., Dweck M.R. Calcification in Aortic Stenosis: The Skeleton Key. J Am Coll Cardiol. 2015 ;66 (5): 561–77. doi: 10.1016/j.jacc.2015.05.066.

15. Oliveira S., Cavalcanti L.R.P., Perazzo Á.M., Gomes R.A.F., Clavel M.A., et al. Calcific Aortic Valve Stenosis and Atherosclerotic Calcification. Curr Atheroscler Rep. 2020; 22 (2): 2. doi: 10.1007/s11883-020-0821-7.

16. Barbarash O.L., Sedykh D.Yu., Khryachkova O.N., Alkhimova T.S., Kashtalap V.V. Efficacy comparison of combined lipid-lowering therapy in patients with acute and chronic coronary artery disease in combination with severe dyslipidemia. RMJ. 2024; 9: 15–19. doi: 10.32364/2225-2282-2024-9-3. (In Russ)

17. Shishkova D.K., Sedykh D.Yu., Hryachkova O.N., Gruzdeva O.V., Kutikhin A.G., Kashtalap V.V. The impact of combination lipid-lowering therapy on parameters of lipid and mineral profile in patients with dyslipidemia, acute coronary syndrome, and chronic coronary syndrome. Complex Issues of Cardiovascular Diseases. 2025; 14 (2): 186–199. doi: 10.17802/2306-1278-2025-14-2-186-199. (In Russ)